drugset / Trial / NCT06957431
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Timeline
- Start
- 2025-10-22
- Primary completion
- 2031-05-31
- Completion
- 2036-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | 1.1 mg/m2 | Intravenous |
| Subject | Zanzalintinib | Small molecule | 20 mg | Oral |
| Subject | Zanzalintinib | Small molecule | 40 mg | Oral |
| Subject | Zanzalintinib | Small molecule | 60 mg | Oral |